MoonLake Immunotherapeutics (MLTX) Income Statement: Revenue & Earnings

MoonLake Immunotherapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

MoonLake Immunotherapeutics income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	112.77	31.80	42.05	12.64
Selling, General & Administrative	30.32	22.32	23.01	21.66
Operating Expenses	143.09	54.12	65.06	34.29
Operating Income	-143.09	-54.12	-65.06	-34.29
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00
Other Income/Expense	22.13	-10.14	0.27	0.00
Income
Income Before Tax	-120.96	-43.98	-64.47	-64.37
Income Tax Expense	0.28	0.09	0.04	0.01
Net Income	-118.94	-36.01	-49.97	-64.37
Net Income - Continuous Operations	-121.24	-44.08	-64.51	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-141.71	-43.58	-64.90	-34.29
EBIT	-143.09	-43.98	-65.06	-34.29
Depreciation & Amortization	1.38	0.40	0.16	0.01
Earnings Per Share
Basic EPS	-2.00	-1.00	-2.00	-8.00
Diluted EPS	-2.00	-1.00	-2.00	-8.00
Basic Shares Outstanding	62.87	49.12	29.36	7.84
Diluted Shares Outstanding	62.87	49.12	29.36	7.84